Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs), and/or external stakeholders.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date.

  • Application Due Date(s): July 15, 2022; Oct 17, 2022; Feb 15, 2023; June 15, 2023; Oct 17, 2023; Feb 15, 2024; June 18, 2024; Oct 17, 2024

PAR-22-167 Expiration Date October 18, 2024

Agency Website

Eligibility Requirements

Only active CTSA Hub prime and partnering organizations are eligible to apply. For both UG3 and UH3 Phases, an application must involve investigators (as PDs/PIs or Co-investigators) who are from prime or partnering organizations where there are currently active CTSA Program hubs as of the due date of the application. Applicants must be from at least 3 eligible organizations and may choose one of the following options:

Option 1 – The UG3/UH3 must include investigators representing at least three different currently active CTSA Program hubs as of the due date of the application.

Option 2 – The UG3/UH3 application must involve investigators from at least two different currently active CTSA Program hubs and one or more currently active organizations from the participating NIH ICOs listed below, as of the due date of the application. For this option, the contact PD/PI named on the application must be an investigator from a prime or partnering organization where there is currently an active CTSA Program hub as of the due date of the application.

The contact PD/PI must be an investigator from a prime or partnering organization where there is currently an active CTSA Program hub as of the due date of the application. Investigators who are not from CTSA hubs(such as investigators who are from a participating organization supported by NIH ICOs and/or external stakeholder),but who wish to bring an innovative project to the CTSA Program, can co-direct a project using the multiple PD/PI option in collaboration with a contact PD/PI.

Amount Description

Direct cost funding support may not exceed $650,000 per year for the UG3 Phase of awards and $650,000 per year for the UH3 Phase awards.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Clinical Science
Medical - Translational

External Deadline

February 15, 2024